A Phase II, Single-arm, Multicenter, Prospective Study of Cardunolizumab in Recurrent or Metastatic Vulvar and Vaginal Cancer

This study is testing an immunotherapy drug called cardunolizumab in women with recurrent or metastatic vulvar or vaginal cancer that cannot be cured with standard treatment. This is a phase II study to see how well the drug works and how safe it is. **You may be eligible if...** - You are between 18 and 75 years old - You have confirmed recurrent or metastatic squamous cell, adenocarcinoma, or adenosquamous carcinoma of the vulva or vagina - Your cancer is not curable and has at least one measurable tumor on imaging - You are in good general health (ECOG 0–1) with a life expectancy of at least 3 months - You have adequate organ function **You may NOT be eligible if...** - You have had prior immunotherapy that was not tolerated or caused severe immune reactions - You have active autoimmune disease - You are pregnant or breastfeeding - You have significant heart, liver, or kidney problems Talk to your doctor to see if this trial is right for you.